Healthcare is now AI’s biggest vertical market.
Spend grew 2.5x to $3.7B this year, more than double legal ($1.8B) and more than legal and finance combined.
It started in paperwork: scribing and billing. Now it’s moving into drug discovery, patient engagement and clinical decision support. Clinical copilots alone grew 5.5x to $550M.
Our 2026 State of AI in Healthcare report from @grgyap, @jpsanday, @CroomBeatty, @hu_j, @derekgxiao and @sabrinarlu: mnlo.vc/2026-healthcare-ai-r…
The whole time I watched this season, I kept wondering how the PM's wife had no security and it made it all less believable.... Turns out it is true IRL.
Keira Knightley and 'Black Doves' Creator Joe Barton Why Helen Should Have Been the One to Kill [SPOILER], That Oner and Hopes for Season 3 variety.com/2026/tv/global/k…
Today, Zipline raised $1.5b at a $21.5b valuation.
When we started Zipline, flying autonomously in the US was illegal. Which made it really hard to convince investors to give us money! But we were too naive to think that meant we shouldn’t try.
We started the company on a cow farm. We worked out of run-down construction trailers so that we could keep engineering, manufacturing, and flight test all unified and in one place. Hiring people from normal companies like Google was hard because we didn’t have a cafe or laundry service. But enough risk takers and rebels wanted to go on an insane adventure with us. They became the early team.
We decided to launch in smaller countries and focus on life-saving use cases. We hired incredible entrepreneurs and operators in Rwanda, Ghana, Cote D’Ivoire, and other countries. For eight years, Zipline expanded our service across Africa, serving thousands of hospitals and health facilities and reducing maternal mortality by 51%. Today, the network saves over 14k lives every year and is cash flow positive.
Last year, Zipline launched at scale in the US and the service exploded. We grew flight volumes about 100x over the last 18 months, and now make more than a million deliveries a year per metro. We’re now expanding with our partners to millions of deliveries per day. Normal families love having access to anything they need in 10-20 minutes, no matter where they live. Spend more time with loved ones and less time worrying about errands.
Zipline builds drone delivery that is silent and safe. No one wants to hear an extremely loud “swarm of bees” delivering to their backyard or their neighbor’s. Automated delivery needs to be insanely quiet, which guided the overall architecture of our technology delivering from 330 ft in the air. We are 6 times quieter than the closest competitor during delivery. Zipline also now has over 150m commercial autonomous miles (10x the rest of the industry combined) and no safety incidents. Neighborhoods should demand silent and safe delivery!
Today, Zipline is announcing two things. First, we just signed the largest autonomous vehicle contract in human history to expand automated delivery nationally with Walmart, our first and biggest partner in the US. We’re starting by scaling to 300 supercenters throughout the country. Second, we’ve raised $1.5b at a $21.5b valuation from existing and new investors, led by Paradigm, WCM, and Layer.
Zipline was a hard company to believe in for the first ten years of our history. Investors didn’t think the company was “investable”. Most people didn’t even think Zipline was an economic venture. Thanks to those who have rooted for us along the way. To all of the tens of millions of customers and families who rely on Zipline day in and day out: thank you for helping us build the future. Zipline has grown more than @ryanzip, @keenanwyrobek, I, and all others at the company could have imagined.
There is a big opportunity to build a new layer of infrastructure for humanity over the coming years. We want to approximate teleportation. We can build a logistics network that connects and serves all people on earth. We can free human flourishing from the choking constraint of traffic and roads. There are no roads where we’re going. 🚀🌎
Excited about what Dulo is building and to work with @SebastianThrun and @adrianaoun. We are honored to be one of their very first investors @overwatervc, ahead of this round!
Sebastian Thrun, who helped launch Google Brain and the self-driving project that became Waymo, is turning his attention to AI-powered engineering. His new startup, Dulo, has raised $130 million to develop models that can design planes, cars and other complex hardware.
More details: thein.fo/4jKJ14n
Scott Kupor (@skupor) was the first hire at Andreessen Horowitz. Marc and Ben still joke that if he had said yes sooner, the firm would be called Andreessen, Kupor, Horowitz.
His job description: "We're going to invest, and you need to figure out everything else."
Scott spent 16 years helping grow a16z from 3 people to about 700. Now he runs the Office of Personnel Management, the HR department for 2 million federal employees.
Scott explains how a16z borrowed Michael Ovitz's playbook from CAA, why only 7% of the federal workforce is under 30, and why 400 million pages of retirement records sit in an underground limestone mine in Pennsylvania.
This is a fascinating conversation about incentives, talent, and what it takes to turn a 2.3-million-person oil tanker.
0:00 Quitting HP mid-financial crisis to join a16z
1:37 His first day
4:00 How a16z copied Michael Ovitz's CAA playbook
10:18 After-hours bourbon in Marc Andreessen's office
13:31 The Skype deal that returned half the first fund
18:37 Why VCs thought marketing was beneath them
21:48 Swallowing his ego as a16z grew
27:12 Why he left a16z to run the government's HR
30:37 Why government is afraid to take any risk
33:24 Why 99.7% of federal employees get a passing grade
36:13 Recruiting 1,000 engineers into government
38:37 Only 7% of the federal workforce is under 30
40:31 Why "a job for life" is the wrong pitch
43:09 Why the government would never have hired Big Balls
46:39 Why DOGE had to be a big bang
48:56 The underground mine with 400 million pages of paper
55:28 Why government has to accept some failure
57:14 How young people can join
Includes paid partnerships.
Ferring Pharma, one of the biggest sellers of fertility drugs used in IVF, plans to acquire the ovary-in-a-dish startup Gameto for up to $1.38B.
Gameto has made iPSC-derived ovarian support cells that help mature human eggs in the lab. Read more @endpts: endpoints.news/ferring-to-ac…
In vitro fertilization was invented in the 1970's by Robert Edwards, and its purpose is to create babies in an embryology lab. In the last fifty years, IVF has become a $30B global industry, and I expect it to grow to a $1 Trillion global industry in the next 5-7 years.
Gameto, a company that marginally improves the IVF experience by reducing hormone injections from 10 days to just 2-3 days, was acquired today by Ferring (a manufacturer of IVF drugs) for ~$1.4B.
I predict that these three technology pillars, which radically change "the embryo" and the experience, will drive the growth of the IVF market:
1) Selecting and narrowing down to the best available embryos (smallest but immediate opportunity): Genetic testing of embryos to discard the embryos that have a disease predisposition, chromosomal abnormalities. Implant the best and most healthy embryos, and sometimes optimize for height and IQ (e.g. Herasight, Orchid, Nucleus). The problem is that most couples are working with a small and limited number of embryos to start with.
2) Increasing the quality and number of embryos: Gene editing of embryos to correct genetic disease or make embryos protected against disease, to make more embryos usable instead of discarding them (what we do at Origin Genomics). There is a multi trillion dollar market for diseases with hereditary causes and no cures or no affordable treatments (e.g. hereditary cancers, alzheimer's, sickle cell, cystic fibrosis, tay-sachs, huntington's). One gene edit at the embryo stage can remove that disease risk for life. And in vitro gametogenesis, early tech that aims to make eggs and embryos from stem cells derived from skin cells (e.g. Conception), highly relevant for older women wanting to have kids and gay couples, but have significant cultural and regulatory hurdles to clear.
3) Improving the general experience (purposely broad for this context): Gameto (acquired for $1.4B) reduces the hormone injection period from 10 days to just 2-3 days by maturing eggs outside the body (called in vitro maturation, IVM). Artificial wombs and surrogacy fall into this general category as well, though artificial wombs are in very very early days and surrogacy has scalability issues. If artificial wombs work, surrogacy will be less relevant. But I predict it's still at least 10 years away. Certain inflection points could accelerate this timeline, such as the fertility crisis, and a space race to Mars to populate and develop a human civilization fit to survive there.
My prediction of the industry timeline:
Genetic testing of embryos (available now)
Shorter hormone stimulation protocols (e.g. IVM), marginal ways to improve the current experience (available now)
Gene editing of embryos (technology is available now, implementation soon)
IVG (5-10+ years)
Artificial Wombs (10+ years)
The next ten years of IVF will look very different from the last fifty. This is the industry that rewrites human reproduction and evolution.
Gameto, mi sexto unicornio, acaba de ser comprado por Ferring por 1.380 millones de dólares
En 2020 hice una donación a la Universidad de Harvard para crear una beca con el nombre de mi padre, Carlos M. Varsavsky, en el laboratorio de George Church, uno de los grandes genetistas del mundo. La beca tenía un solo objetivo: fabricar óvulos humanos en el laboratorio. De ahí salió Gameto.
Mi padre era astrofísico y creó el Instituto Argentino de Radioastronomía. Era un gran profesor, en la universidad y en casa. En una época sin inteligencia artificial, él era la inteligencia artificial para mí: sabía de todo, era la enciclopedia de la familia. Murió joven. La beca lleva su nombre.
Ferring Pharmaceuticals, la farmacéutica suiza especializada en fertilidad, compra Gameto por hasta 1.382,5 millones de dólares. Soy cofundador de Gameto, y esta es la historia de una empresa que nació para hacer una cosa y fue comprada por otra.
Llegué a la fertilidad en 2016 con Prelude Fertility, una red de clínicas de fertilidad en Estados Unidos que monté y que después pasó a formar parte de Inception, hoy la mayor red de clínicas de fertilidad de Norteamérica.
Dentro de esas clínicas aprendí algo que las tasas de éxito no cuentan. La fecundación in vitro (FIV) funciona, pero es brutal. Durante unas dos semanas la mujer se inyecta hormonas para que sus ovarios liberen muchos óvulos a la vez. Eso son unos veintiocho pinchazos, varias ecografías, análisis de sangre, hinchazón y cambios de humor.
Muchas mujeres pasan por eso una vez y no quieren volver a pasar. Cada una que lo deja es un embarazo que nunca llega. Me obsesioné con una pregunta: ¿y si el tratamiento durara tres días en vez de dos semanas?
En 2020, el año de la beca, arrancamos Gameto con unos 3 millones de dólares de amigos y de otros emprendedores, entre ellos Brian Armstrong, el fundador de Coinbase; Jack Abraham, creador de Atomic, un estudio que monta empresas desde cero; y Shervin Pishevar, uno de los primeros inversores de Uber. Fabricar un óvulo resultó enormemente difícil. Nadie en el mundo lo ha conseguido todavía. Pero por el camino hacia el óvulo encontramos algo más útil para las mujeres que están hoy en tratamiento.
La beca pagó el doctorado de Christian Kramme, un genetista californiano que descubrió cómo fabricar en el laboratorio las células que rodean al óvulo dentro del ovario y lo ayudan a madurar. Hoy es el director científico de Gameto.
En 2021 incorporé a Dina Radenkovic Turner como cofundadora y consejera delegada. Tenía 26 años, era médica formada en el University College de Londres, había competido en olimpiadas de matemáticas en su Serbia natal, y es una de las personas más brillantes con las que he trabajado en mi vida. Mucha gente cuestionó que pusiera a alguien tan joven al frente de una empresa de biotecnología. El tiempo nos dio la razón. Lo que tenía era un objetivo casi imposible, fabricar un óvulo humano en el laboratorio, y una beca en Harvard. Dina convirtió eso en una empresa. Miró las células de Christian y vio un producto: si el óvulo todavía quedaba lejos, haríamos en el laboratorio el trabajo del ovario. Eso es Fertilo.
Con Fertilo, la mujer se pone hormonas solo dos o tres días, alrededor de un 80% menos de pinchazos. Sus óvulos se extraen todavía inmaduros y pasan un día en el laboratorio junto a esas células, que hacen el trabajo del ovario. Una vez maduros, se fecundan como en cualquier ciclo de FIV. Las células nunca entran en su cuerpo.
El 16 de diciembre de 2024 nació en Lima el primer bebé concebido así. En agosto de este año ya eran cinco bebés y más de veinte embarazos.
Una mujer que termina un tratamiento de tres días está mucho más dispuesta a volver a por un segundo ciclo, y a por un tercero. Tres ciclos suaves valen más que un ciclo brutal que nadie quiere repetir.
Con la compra de Ferring, Gameto es la sexta empresa que he construido que supera los mil millones de dólares, después de Viatel, Jazztel, Ya.com, Eolia Renovables, que vendimos en 2017, e Inception Fertility, que absorbió a Prelude. Telecomunicaciones, internet, energías limpias, clínicas de fertilidad y ahora biotecnología. Son sectores que no tienen nada en común, y en todos aprendí lo mismo: lo que más importa es el equipo.
Mi idea original, fabricar un óvulo humano en el laboratorio, todavía no ha funcionado. Lo que vale hasta 1.382,5 millones de dólares apareció por el camino, y lo vimos a tiempo.
Gracias a Dina, a Christian y a todo el equipo de Gameto.
Go, Gameto, go, go, go! A new chapter in women's health.
Bloomberg: "The company has the potential to drive the biggest transformation in women’s health since the birth control pill."
"Gameto aims to improve the egg-freezing experience. The technique, which uses stem cells that have been engineered into ovarian support cells, is intended to free patients from the grueling two weeks of injections that prompt ovaries to make enough eggs during fertility treatment. In a Phase 3 trial, patients are only given one or two injections, after which their eggs are extracted and matured by the engineered cells."
"The treatment is already available to patients in Mexico, Peru and Australia, and has been cleared by regulators in nine more countries [and] may also be helpful in treating symptoms of menopause and maintaining ovarian health." — bloomberg.com/news/articles/…
Today's news: "Ferring Pharmaceuticals has signed a $1.4 billion deal to buy Gameto Inc. Ferring is a Swiss maker of drugs used for in-vitro fertilization and reproductive medicine. It’s betting that with its global access to fertility clinics and pharmaceutical distribution, it will be able to popularize Gameto’s therapy"
"Interest in women’s health, historically under studied and underfunded, has heated up among pharmaceutical companies, driven in part by the commercial success of GLP-1 weight loss drugs among women." — bloomberg.com/news/articles/…
Congratulations Dr. Dina Turner and the Gameto team!
Future Ventures is proud to kick off the new year by leading the Series A for Gameto — to support their vision to improve assisted fertility and prolong reproductive longevity by forestalling ovarian aging and menopause.
• prnewswire.com/news-releases…
• techcrunch.com/2022/01/10/wi…